全球生物相似药市场规模、份额、趋势和成长分析报告（2026-2034）

预计生物相似药市场将从 2025 年的 397.3 亿美元成长到 2034 年的 1,529.7 亿美元，2026 年至 2034 年的复合年增长率为 16.16%。

生物相似药市场正进入关键成长阶段，其驱动力来自生物製药专利到期以及监管机构对高性价比替代药物日益增长的支持。未来生物相似药的研发将充分利用先进的细胞株设计、製程优化和人工智慧驱动的预测模型，以确保产品品质、疗效和安全性的一致性。与药物监测平台和即时批次分析的整合将加速监管核准和市场上市进程。

新兴的生物製程技术，例如连续生产、高产量上游工程和精密纯化技术，能够降低生产成本并提高可扩展性。人工智慧辅助的临床试验设计和患者分层缩短了研发週期，同时增强了疗效评估。与数位健康平台的整合实现了对治疗结果和不利事件的即时监测。

未来市场成长将受到医疗保健产业成本控制、全球生物製药的需求以及精准医疗策略应用等因素的驱动。透过结合製程创新、监管资讯和数位化监测，生物相似药将扩大救命生物製药的可及性，从而在全球范围内提高其可负担性和疗效。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球生物相似药市场：依产品划分

• 市场分析、洞察与预测
• 重组非糖基化蛋白
• 重组糖基化蛋白

第五章 全球生物相似药市场：依应用领域划分

• 市场分析、洞察与预测
• 肿瘤学
• 血液疾病
• 生长激素缺乏症
• 类风湿性关节炎
• 慢性疾病与自体免疫疾病
• 其他的

第六章 全球生物相似药市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第七章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第八章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Amgen Inc
  • F Hoffman-La Roche Ltd
  • Sandoz International GmbH
  • Dr. Reddy'S Laboratories Ltd
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc
  • Samsung Biopis
  • Biocon
  • Viatris Inc
  • Celltrion Healthcare Co. Ltd
  • AbbVie Inc

The Biosimilars Market size is expected to reach USD 152.97 Billion in 2034 from USD 39.73 Billion (2025) growing at a CAGR of 16.16% during 2026-2034.

The biosimilars market is entering a critical growth phase as patent expirations of biologics and regulatory support for cost-effective alternatives expand. Future biosimilar development will leverage advanced cell line engineering, process optimization, and AI-driven predictive modeling to ensure consistent quality, efficacy, and safety. Integration with pharmacovigilance platforms and real-time batch analytics will accelerate regulatory approval and market readiness.

Emerging bioprocessing innovations, including continuous manufacturing, high-yield upstream processing, and precision purification technologies, will reduce production costs and improve scalability. AI-assisted clinical trial design and patient stratification will enhance efficacy evaluation while shortening development timelines. Integration with digital health platforms will enable real-time monitoring of treatment outcomes and adverse events.

Future market growth will be driven by healthcare cost containment, global biologics demand, and adoption of precision medicine strategies. By combining process innovation, regulatory intelligence, and digital monitoring, biosimilars will expand access to life-saving biologics, enhancing affordability and treatment efficacy worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Recombinant Non-glycosylated Proteins
• Recombinant Glycosylated Proteins

By Application

• Oncology
• Blood Disorders
• Growth Hormonal Deficiency
• Rheumatoid Arthritis
• Chronic and Autoimmune Disorders
• Others

COMPANIES PROFILED

• Amgen Inc, F HoffmanLa Roche Ltd, Sandoz International GmbH, Dr Reddys Laboratories Ltd, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Samsung Biopis, Biocon, Viatris Inc, Celltrion Healthcare Co Ltd, AbbVie Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BIOSIMILARS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Recombinant Non-glycosylated Proteins Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Recombinant Glycosylated Proteins Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BIOSIMILARS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Blood Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Growth Hormonal Deficiency Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Rheumatoid Arthritis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Chronic and Autoimmune Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BIOSIMILARS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product
  • 6.2.2 By Application
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product
  • 6.3.2 By Application
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product
  • 6.4.2 By Application
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product
  • 6.5.2 By Application
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product
  • 6.6.2 By Application
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL BIOSIMILARS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Amgen Inc
  • 8.2.2 F Hoffman-La Roche Ltd
  • 8.2.3 Sandoz International GmbH
  • 8.2.4 Dr. Reddy'S Laboratories Ltd
  • 8.2.5 Teva Pharmaceutical Industries Ltd
  • 8.2.6 Pfizer Inc
  • 8.2.7 Samsung Biopis
  • 8.2.8 Biocon
  • 8.2.9 Viatris Inc
  • 8.2.10 Celltrion Healthcare Co. Ltd
  • 8.2.11 AbbVie Inc